血清白细胞介素-25与类风湿关节炎的相关性研究被引量：1

下载PDF

导出

摘要目的通过检测类风湿关节炎(RA)患者血清白细胞介素(IL)-25水平,分析其与RA之间的相关性。方法 60例RA患者(RA组)和30例健康体检者(健康对照组),用酶联免疫吸附试验(ELISA)法测定血清IL-25水平,观察RA组临床指标并测定类风湿因子(RF)、C反应蛋白(CRP)、血沉(ESR)、拉环瓜氨酸肽抗体(CCP)等实验室指标水平,分析与IL-25水平相关性。结果 RA组血清IL-25水平高于健康对照组,差异有统计学意义(P<0.01)。不同RA病情时期患者(RA活动组和临床缓解组)血清IL-25水平比较差异无统计学意义(P>0.05),但均高于健康对照组,差异有统计学意义(P<0.05)。RA组血清IL-25水平与ESR、CRP、平均疾病活动度评分(DAS28)无相关性(P>0.05),与RF呈正相关(r=0.406,P<0.05)。结论 RA患者血清IL-25水平与健康人相比明显升高;血清IL-25对RA的诊断具有一定的临床价值;IL-25参与RA的病理过程,并可能参加相关抗体的产生过程。

作者张滨张莹周卉李明赵雪丽朱芸

机构地区潍坊市人民医院风湿免疫科潍坊市妇幼保健院

出处《中国现代药物应用》 2016年第3期16-17,共2页 Chinese Journal of Modern Drug Application

关键词类风湿关节炎白细胞介素-25

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献7

1类风湿关节炎诊断及治疗指南[J].中华风湿病学杂志,2010,14(4):265-270. 被引量：1316
2徐晓玲,梁瑞霞,黄君健,黄翠芬.细胞因子在类风湿关节炎发病机制中的作用[J].生物技术通讯,2008,19(1):111-114. 被引量：36
3Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Thl or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol, 2002, 169(1):443-453.
4唐宏勇,李忆农.IL-25与自身免疫炎症性疾病[J].新医学,2013,44(12):807-812. 被引量：4
5Vincent C, Simon M, Sebbang M, et al. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol, 1998, 25(5):838-846.
6Kroot E J, de Jong BA, Van Leeuwen MA, et al. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum, 2000, 43(8): 1831 - 1835.
7Kaiwen W, Zhaoliang S, Yinxia Z, et al. Changes and significance of IL-25 in chicken collagen II-induced experimental arthritis (CIA). Rheunmtol Int, 2012, 32(8):2331-2338.

二级参考文献61

1Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis[J]. Rheumatology, 2004,43(Suppl-3):Ⅱ-110-Ⅱ116.
2Dayer J M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis[J]. Rheumatology(Oxford), 2003,42 (Suppl 2):3-10.
3Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction [J]. Arthritis Rheum, 2004,50(1):277-290.
4Dayer J M. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis[J]? J Rheumatol Suppl, 2002, 65:10-15.
5Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis [J]. Arthritis Rheum, 2003,48(6):1521-1529.
6Nishimoto N, Yoshizaki K,Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a muhicenter, double-blind, placebo-controlled triM[j]. Arthritis Rheum, 2004,50(6):1761-1769.
7Min S Y, Hwang S Y, Jung Y O, et al. Increase of cyclooxygenase-2 expression by interleukin 15 in rheumatoid synoviocytes [J]. J Rheumatol, 2004,31(5):875-883.
8Hwang S Y, Kim J Y, Kim K W, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and P13-kinase/Akt-dependent pathways[J]. Arthritis Res Ther, 2004,6(2):120-128.
9Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis[J]. Curt Opin Investig Drugs, 2003,4(5):572-577.
10Nanki T, Nagasaka K, Hayashida K, et al. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis[J]. J Immunol, 2001,167(9):5381- 5385.